Cell-Free Enzymatic DNA Manufacturing

Overview

A cell-free alternative to plasmid DNA production using enzymatic synthesis to manufacture GMP-grade DNA starting materials for viral vector and mRNA therapy manufacturing, offering potential safety, speed, and cost advantages over incumbent plasmid fermentation. Cell-free enzymatic DNA manufacturing is positioned as a safer, faster, and more cost-effective alternative to plasmid DNA production — the deeply entrenched incumbent starting material for viral vector manufacturing, mRNA therapies, gene editing, and vaccines — using a process free of the biological risks associated with bacterial plasmid fermentation. Regulatory certification — specifically the MHRA GMP manufacturing certificate — is cited as the critical validation step for cell-free DNA manufacturing, demonstrating clinical suitability and reducing the perceived regulatory risk that deters conservative pharma partners from adopting the technology. (Segment 6 (25:00-30:00))